top of page
Home_banner_3.jpg

Poster List

These resources are for SETGYC Congress delegates only. Please do not share.

Poster List

arrow&v

P01

CAR-T cells

D Sanchez-Martinez

Josep Carreras Leukemia Research Institute; Red Española de Terapias Avanzadas (TERAV) - Instituto de Salud Carlos III (ISCII) (RICORS, RD21/0017/0029)


Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia

P02

CAR-T cells

C Bueno

Josep Carreras Leukemia Research Institute. Campus Clinic. Barcelona. Spain; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC), ISCIII, Madrid, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain.


CD34⁺CD19⁻CD22⁺ B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed therapies

P03

CAR-T cells

B Blanco

Instituto de Investigación Hospital 12 de Octubre (i+12); Hospital Universitario 12 de Octubre; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III


Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers

P04

CAR-T cells

M Tristán-Manzano

LentiStem Biotech


Physiological (TCR-like) regulated lentiviral vectors: a platform for the generation of improved CAR-T cells

P05

CAR-T cells

L García-García

Laboratorio de investigación en Oncohematología, Fundación de Investigación Biomédica, Hospital Infantil Universitario Niño Jesús, Madrid, 28009, Spain


Use of anti-GD2 (Dinutuximab) as a target for CAR-T cells immunotherapy in Neuroblastoma

P06

CAR-T cells

B Díez

Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain


Transposon-based CAR-T cells for lymphoma treatment

P07

CAR-T cells

M Cortijo-Gutiérrez

GENyO


Creation of next generation CAR-T by Repurposing endogenous immune pathways

P08

CAR-T cells

A López

CIEMAT/CIBERER


Generation of CAR-T cells for the treatment of squamous cell carcinomas in Fanconi anemia patients

P09

CAR-T cells

P Justicia-Lirio

GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia; LentiStem Biotech


Development of 4th generation regulated CAR-T cells (iTRUCKs) targeting pancreatic solid tumors

P10

CAR-T cells

K Pavlovic

GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia; Instituto Maimónides de Investigación Biomédica de Córdoba


TCR/HLA-I double knockout CAR-T cells maintain lytic ability with reduced allogenicity

P11

CAR-T cells

P Garcia-Rodriguez

Instituto de Salud Carlos III


Challenges of CAR-T cells in solid tumours: modelling immunotherapy with 3D osteosarcoma cultures

P12

CAR-T cells

P Barbao

IDIBAPS


Chronic antigen exposure induces CAR-T cell loss of function and a dysregulated gene expression profile leading to treatment failure in solid tumors

bottom of page